Newswire and Healthcare Information

Do Hypertensive Drugs Interfere With Erections?

High blood pressure and sex Hypertension is one of the main reasons for the deterioration of an erection. The problem is that the potency is affected directly by the increased pressure increased and by the drugs designed to reduce high blood pressure. Only modern drugs for treating high blood pressure can cope with this problem. Fortunately, in recent years  there are encouraging prospects for those […]

Pharmos Corporation Reports 2011 Second Quarter Results

Iselin NJ, August 8, 2011 – Pharmos Corporation (OTC-PINK: PARS.PK) today reported financial results for the second quarter and six-month period ended June 30, 2011. These results are included in the Company’s Quarterly Report on Form 10-Q which has been filed with the SEC. Second Quarter Ended June 30, 2011 The Company recorded a net loss of $0.5 million, or $0.01 per share, for the second […]

Pharmos Corporation Reports First Quarter 2011 Results

Iselin NJ, April 28, 2011 – Pharmos Corporation (OTCBB: PARS.PK) ISELIN, N.J., April 28, 2011 /PRNewswire/ — Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the first quarter ended March 31, 2011. The Company recorded a net loss of $0.6 million, or $0.01 per share, for the first quarter 2011 compared to a net loss of $0.5 million, or $0.01 per share, in the […]

Pharmos Corporation Reports Fourth Quarter and Full Year 2010 Results

Iselin NJ, February 17, 2011 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2010. These results are included in the Company’s Yearly Report on Form 10-K which has been filed with the SEC. Fourth Quarter Ended December 31, 2010 The Company recorded a net loss of $152,000, or $0.00 per share, for the fourth quarter […]

Pharmos Corporation Reports 2010 Third Quarter Results

Iselin NJ, October 27, 2010 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the third quarter and nine-month period ended September 30, 2010. These results are included in the Company’s Quarterly Report on Form 10-Q which has been filed with the SEC. During the quarter the Company kept expenses to a minimum level while pursuing potential partners for Dextofisopam, its drug for irritable bowel […]

Pharmos Corporation Reports 2010 Second Quarter Results

Iselin NJ, August 4, 2010 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the second quarter and six-month period ended June 30, 2010. These results are included in the Company’s Quarterly Report on Form 10-Q which has been filed with the SEC. During the quarter the Company kept expenses to a minimum level while pursuing potential partners for Dextofisopam, its drug for irritable bowel […]

Pharmos Corporation Reports First Quarter 2010 Results

Iselin NJ, May 12, 2010 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the first quarter ended March 31, 2010. The Company recorded a net loss of $0.5 million, or $0.01 per share, for the first quarter 2010 compared to a net loss of $3.7 million, or $0.14 per share, in the first quarter 2009. Research & development expenses decreased by $1,891,425 or 94% […]

Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results

Iselin NJ, February 22, 2010 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2009. Fourth Quarter Ended December 31, 2009 Pharmos has no revenues at this time. The fourth quarter net income is partly due to a renegotiated milestone requirement that is not expected to be met and the resulting reversal of a previously recorded […]

Pharmos Corporation Reports 2009 Third Quarter Results

Iselin, NJ, November 12, 2009 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the third quarter and nine-month period ended September 30, 2009. Third Quarter Ended September 30, 2009 The Company recorded a net loss of $1.4 million, or $0.02 per share, for the third quarter 2009 compared to a net loss of $2.8 million, or $0.11 per share, in the third quarter 2008. […]

Pharmos Corporation Engages Cowen to Assist the Company with Accelerating a Partnership for Dextofisopam

Iselin NJ, October 21, 2009 – Pharmos Corporation (OTCBB – PARS.PK); on September 14, 2009, Pharmos announced the results of its Phase 2b Dextofisopam trial for the treatment of diarrhea predominant and alternating diarrhea and constipation irritable bowel syndrome. While the results did not achieve statistical significance for the primary endpoint of overall adequate relief due to an unexpectedly high placebo response rate, the drug clearly […]